The primary purpose is to assess the effect of Daclatasvir (DCV)/Asunaprevir (ASV)/BMS-791325 combination therapy on the exposure of Rosuvastatin.
Ask a Question?
Ask your question and our customer service team will answer it as soon as they can. Questions that do not contain personal information may be posted to our help center to be of service to others
Please enter valid email address.
Please enter all required fields.